Gold nanocrystals aim to slow ALS in new trial

NCT ID NCT05299658

Ongoing Disease control Sponsor: Clene Nanomedicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is an open-label extension for people with early amyotrophic lateral sclerosis (ALS) who completed a previous placebo-controlled trial. Participants will take a daily oral dose of CNM-Au8, a suspension of gold nanocrystals, to see if it safely slows disease progression. The trial involves 40 participants and focuses on safety and nerve function measures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CNM-Au8 (a suspension of gold nanocrystals taken orally once daily)
What this could lead to: If successful, this could point toward a treatment that slows the progression of ALS, a devastating nerve disease.
What could go wrong: This is a small, early-phase extension study with only 40 participants. It focuses on safety, not proof of effectiveness, and results may not apply to all ALS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Concord Hospital

Concord, New South Wales, 2139, Australia
Neuroscience Research Australia

Randwick, New South Wales, 2031, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.